Mural Oncology plc

The momentum for this stock is not very good. Mural Oncology plc is not very popular among insiders. Tradey thinks it is not wise to invest in Mural Oncology plc.

News

Mural Oncology to host first virtual Investor Day on September 26

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Mural Oncology to Host First Virtual Investor Day on September 26, 2024

Globe Newswire Company will provide clinical overview and update on late-stage clinical candidate, nemvaleukin alfa, and overview of IL-18 pipeline program Clinicians to share expert perspectives around the...\n more…

BBR Partners LLC Invests $31,000 in Mural Oncology plc (NASDAQ:MURA)

Ticker Report BBR Partners LLC acquired a new stake in Mural Oncology plc (NASDAQ:MURA - Free Report) during the 2nd quarter, HoldingsChannel.com reports. The fund acquired 10,000 shares of the company's stock...\n more…

Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Globe Newswire WALTHAM, Mass. and DUBLIN, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine...\n more…

Financial Survey: Mural Oncology (NASDAQ:MURA) and Ovid Therapeutics (NASDAQ:OVID)

Ticker Report Ovid Therapeutics (NASDAQ:OVID - Get Free Report) and Mural Oncology (NASDAQ:MURA - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the...\n more…

Mural Oncology to Present at Two Upcoming Investor Conferences

Globe Newswire WALTHAM, Mass. and DUBLIN, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine...\n more…